Clinical Trials
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S1800E
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Status Notes
Effective April 28, 2025 at 12:00 p.m. Pacific Time, sub-study S1800E will be open to accrual. This is a potential FDA Registration Trial. Additional site requirements include:
• maintenance of a Trial Master File (See the Trial Master File guidance document, accessible from the Protocol Workbench at https://www.swog.org/clinical-trials/protocol-workbench)
• completion of a protocol specific Delegation of Task Log (DTL) (see Section 13.2)
• additional monitoring (see Section 18.3)
• maintenance of a Trial Master File (See the Trial Master File guidance document, accessible from the Protocol Workbench at https://www.swog.org/clinical-trials/protocol-workbench)
• completion of a protocol specific Delegation of Task Log (DTL) (see Section 13.2)
• additional monitoring (see Section 18.3)
Research Committee(s)
LungMAP
Lung Cancer
Activated
04-28-2025
ClinicalTrials.gov Registry Number
NCT06616584
Open
Phase
Accrual
3%
SWOG Clinical Trial Number
MM1OA-S03
A Randomized Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML: A myeloMATCH Substudy
Research Committee(s)
myeloMATCH
Leukemia
Activated
04-01-2025
ClinicalTrials.gov Registry Number
NCT06672146
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S2414
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Status Notes
Initial Activation-Effective March 14, 2025, at 12:00 p.m. Pacific Time
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03-14-2025
ClinicalTrials.gov Registry Number
06498635
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S2408
A Randomized Phase III Blinded Trial of lanreotide for the Prevention of Postoperative Pancreatic Fistula
Research Committee(s)
Palliative and End of Life Care Committee
Gastrointestinal Cancer
Activated
02-14-2025
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S1900J
A Phase II Study of Amivantamab SC (subcutaneous) in Participants Previously Treated with High MET-Amplification for Stage IV or Recurrent Non-Small-Cell Lung Cancer (Lung-MAP Sub-Study)
Status Notes
S1900J will open to accrual September 27, 2024, effective 3:00 p.m. EST.
Research Committee(s)
LungMAP
Activated
09-27-2024
ClinicalTrials.gov Registry Number
NCT06116682
Open
Phase
Accrual
5%
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Status Notes
S2312 active as of 9/3/2024.
Research Committee(s)
Genitourinary Cancer
Activated
09-03-2024
ClinicalTrials.gov Registry Number
06470243